Compare ATPC & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATPC | INDP |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.5M |
| IPO Year | 2017 | 2021 |
| Metric | ATPC | INDP |
|---|---|---|
| Price | $3.13 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 26.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,322,747.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.05 | $0.27 |
| 52 Week High | $6.30 | $13.24 |
| Indicator | ATPC | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 44.14 |
| Support Level | $1.28 | $1.64 |
| Resistance Level | $3.59 | $1.99 |
| Average True Range (ATR) | 0.52 | 0.15 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 70.44 | 38.00 |
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.